Flavopiridol (alvocidib), the first CDK inhibitor to enter clinical trials, is the most potent CDK9 inhibitor identified to date and has demonstrated marked anti-tumor activity in chronic lymphocytic leukemia (CLL) [11, 12]. Here, CDK9 is linked to B-cell chronic lymphocytic leukemia.